A drone platform links to its autopilot and uses onboard sensors to enable autonomous flight

Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) said a government defense customer exercised an option under its prime contractor agreement for a MIL-STD vehicle-mounted audio-based system for armored fighting vehicles. The option expands contract value by about $184,000 to about $534,000, with deliveries expected by the overall project schedule.

Amgen (AMGN) reported 10% revenue growth in Q2, with Tezspire sales up 42%. However, earnings per share rose just 4%, raising questions about earnings growth. The company's newer drugs, like Repatha and Imdelltra, drove growth, but older drugs face biosimilar competition. MariTide, an obesity drug, is a key focus for future earnings.

Bolt plans to use Nvidia's Alpamayo Stack software for autonomous driving in 25,000 Lucid vehicles in Europe, starting with a data-collection program in Madrid in 2027. Bolt and Nvidia will adapt the system to European road conditions. Lucid's potential robotaxi volume reaches 60,000 vehicles with existing partnerships.

Anthropic has committed nearly $90 billion to secure compute infrastructure, including $44.6 billion confirmed in an SEC filing and another $45 billion in negotiations. The deals target the Monarch Compute Campus in West Virginia, highlighting the shift in focus from model weights to power control. DeepSeek and llm-d released open-source software, reducing costs and commoditizing the inference stack.

Lucid's 25,000 Bolt robotaxis will use Nvidia's Alpamayo Stack self-driving software, starting with data collection in Madrid in 2027. Lucid has robotaxi deals with Nuro for Uber and Nvidia for Bolt. Bolt aims for 100,000 autonomous vehicles by 2035. Lucid's robotaxi orders total 60,000 vehicles, nearly four years of current deliveries.

Novo Nordisk reported phase 3 results for its obesity drug CagriSema, showing 25% average weight loss in women after 68 weeks. The study included 2,300+ women, with varying results across menopausal categories. CagriSema combines cagrilintide and semaglutide, aiming to compete with Eli Lilly's obesity treatments.